Hong Kong Journal of Nephrology
Volume 8, Issue 1 , Pages 17-23, April 2006

Comparison of Atorvastatin and Simvastatin in the Long-term Treatment of Hyperlipidemia After Kidney Transplantation

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China

Article Outline

Background

Hyperlipidemia is a common complication after kidney transplantation. However, there is little long-term data on the efficacy and tolerability of statin therapy in kidney transplant recipients.

Methods

We performed a prospective 3-year study to investigate the effects of atorvastatin treatment in 15 hypercholesterolemic stable renal allograft recipients on maintenance immunosuppression with corticosteroid and cyclosporine. Results were compared with data from 15 historical controls matched for baseline hyperlipidemia and renal allograft function who had been treated with simvastatin.

Results

Patients in the two treatment groups showed similar baseline characteristics. The average dosages of atorvastatin and simvastatin were 9.25 ? 2.82 mg and 8.38 ? 1.86 mg, respectively. Atorvastatin treatment reduced total cholesterol (TC) by 31.1%, 27.7%, 25.9% and 28.9%, and low-density lipoprotein (LDL) by 43.4%, 37.4%, 36.8% and 41.6%, after 3, 12, 24 and 36 months of treatment, respectively. A significant reduction in triglycerides (TG) was noted after 3 and 9 months, but was not sustained. High-density lipoprotein levels were unaltered. Reductions in TC and LDL after simvastatin treatment appeared less pronounced, although the differences did not reach statistical significance. At last follow-up, 90.9% of atorvastatin-treated patients achieved target LDL of less than 3.4 mmol/L, compared with 78.6% of the simvastatin group. No patients developed adverse reactions including abnormalities in liver enzyme or creatine kinase levels. Acute rejection was not observed, although one patient on simvastatin developed chronic allograft nephropathy.

Conclusion

Atorvastatin and simvastatin demonstrated sustained efficacy in reducing the levels of TC and LDL in stable renal allograft recipients. While atorvastatin may be more potent than simvastatin in the treatment of hypercholesterolemia, its TG-lowering effect was not sustained with long-term treatment. The difference in the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves.

Key words:  atorvastatin , hypercholesterolemia , kidney transplantation , simvastatin

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Andany MA , Kasiske BL . Dyslipidemia and its management after renal transplantation . J Nephrol . 2001;14(Suppl 4):S81–S88
  2. Hricik DE , Mayes JT , Schulak JA . Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia . Am J Kidney Dis . 1991;18:353–358
  3. Kobashigawa JA , Kasiske BL . Hyperlipidemia in solid organ transplantation . Transplantation . 1997;63:331–338
  4. Pannus HS , Singh D , Sandhu JS . Lipid profile before and after renal transplantation - a longitudinal study . Ren Fail . 2003;25:411–417
  5. Quaschning T , Mainka T , Nauck M , Rump LC , Wanner C , Kramer-Guth A . Immunosuppression enhances atherogenicity of lipid profile after transplantation . Kidney Int Suppl . 1999;71:S235–S237
  6. Hines L . Can low-fat/cholesterol nutrition counselling improve food intake habits and hyperlipidemia of renal transplant patients? . J Ren Nutr . 2000;10:30–35
  7. Tonstad S , Holdaas H , Gorbitz C , Ose L . Is dietary intervention effective in post-transplant hyperlipidemia? . Nephrol Dial Transplant . 1995;10:82–85
  8. Arnadottir M , Berg AL . Treatment of hyperlipidemia in renal transplant recipients . Transplantation . 1997;63:339–345
  9. Massey ZA , Kasiske BL . Post-transplant hyperlipidemia: mechanisms and management . J Am Soc Nephrol . 1996;7:971–977
  10. Jones P , Kafonek S , Laurora I , Hunninghake D . Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The Curves Study) . Am J Cardiol . 1998;81:582–587
  11. Renders L , Mayer-Kadner I , Koch C , Scharffe S , Burkhardt K , Veelken R , et al.   Efficacy and drug interactions of the new HMG CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients . Nephrol Dial Transplant . 2001;16:141–146
  12. Martinez-Castelao A, Grinyo JM, Gil-Vernet S, Seron D, Castineiras MJ, Ramos R, et al. Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression . Transplant Proc . 2002;34:398–400
  13. Lepre F , Rigby R , Hawley C , Saltissi D , Brown A , Walsh Z . A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidemia in renal allograft recipients . Clin Transplant . 1999;13:520–525
  14. Rehman MA , al-Sulaiman MH , Mousa DH , al-Hawas FA , Abdalla AH , Rassoul Z , et al.   Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine . Transplantation . 1995;60:397–399
  15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults  . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  16. Vathsala A , Weinberg RB , Schoenberg L , Grevel J , Goldstein RA , Van Buren CT , et al.   Lipid abnormalities in cyclosporineprednisone-treated renal transplant recipients . Transplantation . 1989;48:37–43
  17. Capone D , Stanziale P , Gentile A , Imperatore P , Pellegrino T , Basile V . Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients . Am J Nephrol . 1999;19:411–415
  18. Chan TM , Cheng IKP , Tam SCF . Hyperlipidemia after renal transplantation: treatment with gemfibrozil . Nephron . 1994;67:317–321
  19. Alvarez ML , Errasti P , Gomez G , Lavilla FJ , Garcia N , Ballester B , et al.   Effect of atorvastatin on the treatment of hyper-cholesterolemia after renal transplantation . Transplant Proc . 1999;31:2328–2329
  20. Davidson M , Mckenny J , Stein E , Schrott H , Bakker-Arkema R , Fayyad R , et al.   Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia . Am J Cardiol . 1997;79:1475–1481
  21. Danesh FR , Anel RL , Zeng L , Lomasney J , Sahai A , Kanwar YS . Immunomodulatory effects of HMG-CoA reductase inhibitors . Arch Immunol Ther Exp . 2003;51:139–148
  22. Bakker-Arkema R , Davidson M , Goldstein R , Davignon J , Isaacsohn JL , Weiss SR , et al.   Efficacy and safety of a new HMG-Co A reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia . JAMA . 1996;275:128–133
  23. Asberg A , Hartmann A , Fjeldsa E , Holdaas H . Atorvastatin improves endothelial function in renal-transplant recipients . Nephrol Dial Transplant . 2001;16:1920–1924
  24. Mora C , Rodriguez ML , Navarro JF . Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin . Transplantation . 2001;72:551
  25. Holdaas H , Fellstrom B , Jardine AG , Holme I , Nyberg G , Fauchald P , et al.   Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial . Lancet . 2003;361:2024–2031
  26. Romero R , Calvino J , Rodriguez J , Sanchez-Guisande D . Short-term effect of atorvastatin in hypercholesterolaemic renaltransplant patients unresponsive to other statins . Nephrol Dial Transplant . 2000;15:1446–1449
  27. Demetriou D , Shabpar A , Bohmig G , Schmaldienst S , Horl WH , Watschinger B . Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation . Wien Klin Wochenschr . 2000;112:358–361
  28. Austin MA , Hokanson JE , Edwards KL . Hypertriglyceridemia as a cardiovascular risk factor . Am J Cardiol . 1998;81:7B–12B
  29. Asberg A , Hartmann A , Fjeldsa E , Bergan S , Holdaas H . Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients . Am J Transplant . 2001;1:382–386
  30. Marz W , Koenig W . HMG-CoA reductase inhibition: antiinflammatory effects beyond lipid lowering? . J Cardiovasc Risk . 2003;10:169–179
  31. Blanco-Colio LM , Tunon J , Martin-Ventura JL , Egido J . Anti-inflammatory and immunomodulatory effects of statins . Kidney Int . 2003;63:12–23
  32. Crisby M . Modulation of the inflammatory process by statins . Drugs Today . 2003;39:137–143
  33. Kendrick E . Cardiovascular disease and the renal transplant recipient . Am J Kidney Dis . 2001;38(6 Suppl 6):S36–S43
  34. Guijarro C , Massy ZA , Kasiske BL . Clinical correlation between renal allograft failure and hyperlipidemia . Kidney Int Suppl . 1995;52:S56–S59
  35. Dimeny E , Wahlberg J , Lithell H , Fellstrom B . Hyperlipidemia in renal transplantation -risk factor for long-term graft outcome . Eur J Clin Invest . 1995;25:574–583

PII: S1561-5413(09)60225-8

doi:10.1016/S1561-5413(09)60225-8

Hong Kong Journal of Nephrology
Volume 8, Issue 1 , Pages 17-23, April 2006

Article Tools